Use of buckysome or carbon nanotube for drug delivery

1 - 34 . (canceled)

35 . A substituted fullerene, comprising:

a fullerene moiety comprising n carbon atoms, wherein n is an integer and 60≦n≦240, and

a functional group selected from the group consisting of biotin-containing moieties, antigen-binding moieties, and tissue-recognition moieties.

36 . The substituted fullerene of claim 35 , comprising structure I:

(B) b —C n -(A) a   (I)

wherein C n is a fullerene moiety comprising n carbon atoms, wherein n is an integer and 60≦n≦240;

B is an organic moiety comprising from 1 to about 40 polar headgroup moieties;

b is an integer and 1≦b≦5;

each B is covalently bonded to the C n through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds;

A is an organic moiety comprising a terminus proximal to the C n and one or more termini distal to the C n , wherein the termini distal to the C n each comprise —C x H y , wherein x is an integer and8≦x≦24, and y is an integer and 1≦y≦2x+1;

a is an integer, 1≦a≦5;

2≦b+a≦6; and

each A is covalently bonded to the C n through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds,

wherein the functional group is covalently linked to a B group.

37 . The substituted fullerene of claim 36 , wherein B comprises 18 polar headgroup moieties; A comprises two termini distal to the C n ; x=12; y=25; b=1; and a=5.

38 . The substituted fullerene of claim 37 , comprising structure II:

wherein X′ is >C(C(═O)OC 3 H 6 C(═O)NHC(C 2 H 4 C(═O)NHC(C 2 H 4 C(═O)OH) 3 ) 3 ) 2 or a functional-group substituted >C(C(═O)OC 3 H 6 C(═O)NHC(C 2 H 4 C(═O)NHC(C 2 H 4 C(═O)OH) 3 ) 3 ) 2 , and each X is >C(C(═O)O(CH 2 ) 11 CH 3 ) 2 .

39 . The substituted fullerene of claim 35 , further comprising a therapeutic moiety associated with the fullerene moiety.

40 . The substituted fullerene of claim 39 , wherein the therapeutic moiety is an anti-cancer drug.

41 . A method of administering a therapeutic agent to a mammal, comprising:

(i) administering a solution comprising (a) a substituted fullerene comprising (a-i) a fullerene moiety comprising n carbon atoms, wherein n is an integer and 60≦n≦240, and (a-ii) a functional group selected from the group consisting of biotin-containing moieties, antigen-binding moieties, and tissue-recognition moieties, and (b) a pharmaceutically effective amount of the therapeutic agent, wherein the therapeutic agent is associated with the substituted fullerene.

42 . The method of claim 41 , wherein the therapeutic agent is an anti-cancer drug.

43 . The method of claim 41 , further comprising

administering an adjuvant to the mammal, wherein the adjuvant facilitates dissociation of the therapeutic agent from the substituted fullerene.

44 . (canceled)